All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-05-19.
From the record
Palvella Therapeutics, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2023-05-19) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+26% a year over 10 filed years; profitable in 1 of 8.
From the record
Palvella Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $5 million in fiscal 2014 to $43 million in fiscal 2023, up 26% a year; it rose in 6 of 9 years; the deepest fall was 45% from fiscal 2014 to fiscal 2015; net income was positive in 1 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 9.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Palvella Therapeutics, Inc.'s shareholder treatment is put at 9.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 1% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -149%: lost 149¢ per shareholder dollar. Leverage 53%: owes 53¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Palvella Therapeutics, Inc. lost about 149 cents for every dollar of shareholders' money. Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count grew 405.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 32% of 315 in its family; net margin 43.7%.
From the record
Palvella Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $43 million in fiscal 2023 ranks in the top 46% by size; a net margin of 43.7% ranks in the top 6%; revenue growth of 13.5% a year over the last 3 filed years ranks in the top 44% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Palvella Therapeutics, Inc.'s leadership is put at 4.5 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 45% of 415 in its family; the record of its people begins on 2024-12-16 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 1.9 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
SI estimate 9.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Palvella Therapeutics, Inc.'s room to expand is put at 9.8 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 2% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 35% of 306 in its family for growth drivers.
From the record
Palvella Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2023: revenue grew 13.5% a year over the last three filed years against 26% over all 10, slowing (bottom 30% of its family); the newest year grew 65.3% (top 20%); research spending grew -24.5% a year (bottom 16%); capital spending grew -60.3% a year (bottom 13%) (its annual reports). Palvella Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 18% of 233 in its family for expectations against reality.
From the record
Palvella Therapeutics, Inc.'s newest year against its own record: revenue of $43 million in fiscal 2023 came in 75.9% above the $24 million its prior three years' pace pointed to (top 17% of its family); net income of $19 million against a prior three-year average of $39 million (top 11%); a net margin of 43.7% against losses larger than its revenue before (top 27%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made